In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 1 to 50 of 386

TitleTypeExpected publication date
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]Technology appraisal guidance
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]Technology appraisal guidanceTBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]Technology appraisal guidanceTBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]Technology appraisal guidanceTBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Technology appraisal guidance
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia [ID6232]Technology appraisal guidance
Advanced breast cancer: diagnosis and management (Partial update)NICE guideline
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]Technology appraisal guidance
Aggressive behaviour in people receiving NHS or social careQuality standard
Aggressive behaviour in people receiving NHS or social care: prevention and managementNICE guideline
Alcohol Use Disorders (update)NICE guidelineTBC
ALXN1840 for treating Wilson disease [ID6422]Technology appraisal guidanceTBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]Technology appraisal guidance
Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]Technology appraisal guidanceTBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]Highly specialised technologyTBC
Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]Technology appraisal guidanceTBC
Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]Technology appraisal guidance
Artificial intelligence (AI) technologies to help detect prostate cancer on MRIHealth technology evaluation
Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value AssessmentHealth technology evaluation
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]Technology appraisal guidanceTBC
Asunercept for treating glioblastoma [ID1301]Technology appraisal guidanceTBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]Technology appraisal guidanceTBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Technology appraisal guidanceTBC
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]Technology appraisal guidanceTBC
Atogepant for treating migraine [ID6615]Technology appraisal guidance
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Technology appraisal guidanceTBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]Technology appraisal guidanceTBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Technology appraisal guidanceTBC
Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]Technology appraisal guidance
Avelumab for previously treated platinum-resistant ovarian cancer [ID1497]Technology appraisal guidanceTBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Technology appraisal guidanceTBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]Technology appraisal guidanceTBC
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]Technology appraisal guidanceTBC
Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]Technology appraisal guidanceTBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]Technology appraisal guidanceTBC
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]Technology appraisal guidance
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]Technology appraisal guidanceTBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]Technology appraisal guidanceTBC
Bepirovirsen for treating chronic hepatitis B [ID6608]Technology appraisal guidanceTBC
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]Technology appraisal guidance
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]Technology appraisal guidance
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
Bipolar disorder: assessment and management (extraordinary review)NICE guidelineTBC
Bladder cancer: diagnosis and management (update)NICE guidelineTBC
Botulinum toxin type A for preventing episodic migraine [ID6450]Technology appraisal guidanceTBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]Technology appraisal guidanceTBC
Breast cancer guidelinesNICE guidelineTBC
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All